$154.78
-0.57-0.37%
Last update: Nov 11, 4:24 PM
Guardant Health Inc
GHNASDAQ
Guardant Health rose 58.4% from $97.71 to $154.78, ahead of the S&P 500's +9.8%. Its worst day was Apr 10 (−9.8%), and its low came Apr 10 at $78.60.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Guardant Health shares rose 10.3%, while the S&P 500 rose 0.6%.
+10.3% · S&P 500 +0.6%
EPS of $-0.50 beat the $-0.61 estimate on $281.3M revenue (est. $275.4M); FY revenue guidance of $1.3B–$1.3B against the $1.2B consensus.
Story events cover the past 12 months · Times ET
−3.1% · S&P 500 +0.7%
Guardant Health closed at its lowest level of the year, 19.6% below where the year started.
−9.8%, the year's worst day · S&P 500 −0.1%
EPS of $-0.45 beat the $-0.52 estimate on $301.7M revenue (est. $278.9M); FY revenue guidance of $1.3B–$1.3B against the $1.3B consensus.
+3.7% · S&P 500 +0.8%
Guardant Health’s new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood drawApproval strengthens Guardant’s leadership in
+17.1%, the year's best day · S&P 500 +1.0%
Guardant Health shares rose 13.8%, while the S&P 500 fell 0.1%.
+13.8% · S&P 500 −0.1%
EPS of $-0.42 beat the $-0.46 estimate on $335.0M revenue (est. $314.9M); FY revenue guidance of $1.3B–$1.4B against the $1.3B consensus.
+6.3% · S&P 500 +0.7%
Guardant Health closed at its highest level of the year, 91.6% above where the year started.
+5.3% · S&P 500 +0.7%
EPS of $-0.29 beat the $-0.39 estimate on $361.0M revenue (est. $350.7M); FY revenue guidance of $1.4B–$1.4B against the $1.4B consensus.
−1.7% · S&P 500 +0.3%
Where it ended: a close of $154.78 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $-0.38, revenue est. $371.1M).
Nothing in the past 12 months.
All GH dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GH and SPY from Benzinga historical bars. Not investment advice.
